Discover more insights into Osimertinib Therapy 오시머티닙 요법

Keywords frequently search together with Osimertinib Therapy 오시머티닙 요법

Narrow sentence examples with built-in keyword filters

Osimertinib Therapy sentence examples within non small cell



Machine Learning-Based CT Radiomics Analysis for Prognostic Prediction in Metastatic Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation Receiving Third-Generation EGFR-TKI Osimertinib Treatment


The prognostic value of longitudinal circulating tumor DNA profiling during osimertinib treatment.

Osimertinib Therapy sentence examples within Line Osimertinib Therapy



NGS-Based ctDNA Profiling After the Resistance of Second-Line Osimertinib for Patient with EGFR-Mutated Pulmonary Adenocarcinoma


Cost-effectiveness analysis of different sequences of osimertinib administration for epidermal growth factor receptor-mutated non-small-cell lung cancer

Osimertinib Therapy sentence examples within Received Osimertinib Therapy



Different Survival Benefit of Osimertinib in Different Sequences: A Real‐World Outcome of Osimertinib Treatment in Pretreated T790M-Positive Advanced NSCLC in Taiwan


The prognostic value of longitudinal circulating tumor DNA profiling during osimertinib treatment.


Learn more from Osimertinib Therapy 오시머티닙 요법



Osimertinib



Osimertinib



Acute Lower Extremity Arterial Thrombosis Associated with Osimertinib-Induced Erythrocytosis



Cabozantinib/osimertinib



Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer



Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR



Standard-Dose Osimertinib in EGFR-Mutated Non–Small-Cell Lung Adenocarcinoma With Leptomeningeal Disease



Osimertinib is an effective epidermal growth factor receptor-tyrosine kinase inhibitor choice for lung cancer with epidermal growth factor receptor exon 18-25 kinase domain duplication: report of two cases.



A comprehensive prognostic analysis of osimertinib treatment in advanced non-small cell lung cancer patients with acquired EGFR-T790M mutation: a real-world study



The emergence of various genetic alterations mediated the Osimertinib resistance of a patient harboring heterozygous germline EGFR T790M: a case report.



Possibility of brigatinib-based therapy, or chemotherapy plus anti-angiogenic treatment after resistance of osimertinib harboring EGFR T790M-cis-C797S mutations in lung adenocarcinoma patients.



Predictive factors testing proposal for NSCLC patients during the COVID-19 pandemic



Somatic Copy-Number Alterations in Plasma Circulating Tumor DNA from Advanced EGFR-Mutated Lung Adenocarcinoma Patients



1766. Osimertinib-Associated Progressive Multifocal Leucoencephalopathy



Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study.



Osimertinib and jaw osteonecrosis? A case report



Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib



Case report: Management of Progressive Lung Cancer Patients after First-Line EGFR Tyrosine Kinase Inhibitor Therapy



Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib



Rapid effect of osimertinib re-challenge on brain metastases developing during salvage cytotoxic chemotherapy after osimertinib treatment failure: A case report.



Abstract 2237: Detection of CK-19 mRNA positive CTCs, isolated with a size-based microfluidics platform, in NSCLC patients under osimertinib therapy



Association between TP53 mutations and efficacy of Osimertinib for brain metastasis from EGFR-mutant lung cancer



Screening system for epidermal growth factor receptor mutation detection in cytology cell‐free DNA of cerebrospinal fluid based on assured sample quality



Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study



Exon-16-skipping HER2 as a novel mechanism of osimertinib-resistance in EGFR L858R/T790M-positive non-small-cell lung cancer.



Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.



Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib


Learn more from Osimertinib Therapy 오시머티닙 요법

Osimertinib Therapy 오시머티닙 요법


Osimertinib Therapy 오시머티닙 요법
Encyclopedia 백과사전